South Africa Launches Patient-Led Cancer Registry

By Crystal Lubbe

March 4, 2025

Are we truly capturing the full landscape of cancer care in South Africa? South Africa has initiated a new approach to cancer data collection by introducing a patient-led cancer registry. This is in collaboration with the National Cancer Registry (NCR) and the non-governmental organization Living with Cancer South Africa. This initiative aims to fill data gaps and improve the accuracy of cancer statistics, which are currently limited by a pathology-based system that may miss diagnoses made outside laboratory settings.

Key Insights

Patients or their loved ones can now register cancer details online, providing a more comprehensive picture of cancer incidence in South Africa. The existing pathology-based system has been inadequate, particularly for cancers diagnosed through radiology, tumor markers, or clinical deduction rather than biopsies. Enhanced data will assist in better resource allocation and the development of data-driven cancer policies.  The new system also allows for recording historic cancer cases, including those of deceased individuals, to enrich the overall data.

Patient Cancer Registry

Established in 1986, the NCR has been the primary source of national cancer incidence data in South Africa. It uses a pathology-based surveillance system, which has limitations including heavy reliance on laboratory data and the potential to miss cases diagnosed through other methods. The use of both active and passive case-finding methods is crucial for improving the completeness and accuracy of cancer registry data. This is evidenced by other South African cancer registries like the Eastern Cape Cancer Registry. According to the World Health Organization, Africa faces a significant cancer burden, with around 1.1 million new cancer cases and 700,000 deaths annually. Accurate data collection through the patient-led cancer registry is essential for effectively addressing this crisis.

Health Implications

Improved cancer data will enable better resource allocation and more effective policy-making, enhancing cancer care and outcomes. This can optimize healthcare spending by targeting resources to areas with the highest need. Accurate and comprehensive data will aid in developing more targeted and effective cancer prevention and control strategies. Therefore, potentially leading to improved survival rates and better patient outcomes. Data-driven policies can be more effective in addressing the cancer burden. Involving patients in the reporting process ensures that policies are patient-centered and responsive to real-world needs.

By identifying and filling data gaps, South Africa can use its resources more efficiently. As a result, cancer care will become both accessible and effective across different regions and populations.

The patient-led cancer registry emphasises the importance of patient involvement in improving the accuracy and comprehensiveness of cancer data.

Reference url

Recent Posts

Zimislecel type 1 diabetes
   

Cell Therapy for Type 1 Diabetes: Vertex Trial Results and Market Potential

🚀 What if we could revolutionize Type 1 diabetes treatment?

Vertex Pharmaceuticals has made significant strides with its promising phase 1/2 trial results for **zimislecel**, a stem cell-derived therapy that not only restores insulin production but also drastically reduces severe hypoglycemic events. As phase 3 trials commence, this breakthrough could reshape care for T1D patients and potentially reduce long-term healthcare costs.

Curious to learn how zimislecel and other potential cell therapies may redefine diabetes management? Click to read more!

#SyenzaNews #biotechnology #HealthEconomics

biosimilar clinical approach
    

Biosimilar Clinical Approach

🚀 How is the EMA’s new biosimilar clinical approach changing the landscape of drug approvals in Europe?

With a focus on tailored clinical assessments, the EMA is streamlining the pathway for biosimilars by allowing analytical data to take precedence over large-scale comparative efficacy studies. This shift promises to enhance patient access to life-saving therapies while maintaining rigorous safety standards.

Dive deeper into the implications of this innovative regulatory approach and find out how it can impact health economics and market access.

👉 Read more in the full article!
#SyenzaNews #regulatoryaffairs #MarketAccess

HIV prevention injection
   

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Prevention

🌍 Will Yeztugo Approval and Access Strategy Deliver an Inflection Point in HIV/AIDS?

Yeztugo (lenacapavir), a twice-yearly injection, redefines long-acting HIV prevention with 96–100% efficacy. Gilead’s access strategy—insurance, assistance, and generics for 120 countries—targets global impact. Can it balance $28,218 U.S. costs with equity for 1.3M annual infections? My article explores health economics, public health, and market dynamics.

📖 Read how Yeztugo’s access strategy could transform long-acting HIV prevention

#SyenzaNews #GlobalHealth #HIVPrevention #Yeztugo #PrEP

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.